ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1072

Sex Ratio of Offspring Born to Women with Lupus and Rheumatoid Arthritis

Elizabeth V. Arkema1, Johan Askling1, Jane Salmon2 and Julia F Simard3, 1Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: pregnancy, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Public Health (ACR): Rheumatoid Arthritis and Systemic Lupus Erythematosus Outcomes

Session Type: Abstract Submissions (ACR)

Background/Purpose: Women with SLE are at increased risk for pregnancy complications and specific autoantibodies may result in preferential loss of female offspring. Studies on the male to female (M:F) sex ratio of births in the SLE population have been contradictory. We used a large national population-based cohort of patients with SLE to determine whether the M:F ratio of births to mothers with SLE is different than the general population as well as a population of women with rheumatoid arthritis (RA) to estimate the ratio in another chronic inflammatory disease.

Methods: SLE was defined as ≥2 visits in inpatient or outpatient care (National Patient Register (NPR); 1969-2011) listing an SLE ICD code with ≥1 SLE-coded visit to a specialist. A sample of general population comparators was identified from the Total Population Register. Women with a delivery were identified from the Swedish Medical Birth Register (1973-2011). We used modified Poisson regression with robust sandwich estimators to calculate the risk ratio (RR) for having a male offspring associated with an SLE diagnosis adjusted for age, year and maternal country of birth. Our primary analysis was restricted to first singleton births only. In secondary analyses, we examined all births and restricted to live births only. We also examined antiphospholipid syndrome (APS) history in the SLE population using any ICD10 code before or at delivery, restricted to ≥1997 when the code was available. Lastly, we calculated the M:F ratio of offspring born to women with ≥2 RA-coded visits in the NPR with ≥1 visit to a specialist before delivery.

Results: We identified 604 women with SLE before their first delivery and 1289 singleton deliveries total to women with prevalent SLE. Maternal SLE at delivery had a lower proportion of male offspring compared to the general population. The RR for male offspring associated with SLE was 0.95 (95%CI 0.88, 1.04) for first births and 0.96 (95%CI 0.90, 1.01) for all singleton births (Table). RRs did not change with adjustment by age, year or country of birth. Results were similar among live births only and including multiples. Women with both APS and SLE had a lower odds of having a male child compared to the general population. We identified 1136 women with prevalent RA at first delivery and 2674 singleton deliveries total. The M:F ratio in RA was not significantly different than the general population (first birth RR=0.96 (95%CI 0.91, 1.02), all births OR=0.99 (95%CI 0.95, 1.03)).

Conclusion: We observed a lower proportion of male offspring born to women with prevalent SLE at delivery compared to the general population, which was not statistically significant. We observed a significantly lower odds of male offspring born to women with SLE and APS when all births were considered. In this large study using similar techniques to identify patients as that of a group in Canada, we did not confirm their findings of a male dominance in offspring.

Table. Maternal characteristics and M:F sex ratio among deliveries in Sweden, 1973-2011, comparing mothers with SLE at delivery to mothers from the general population restricted to singleton births

 

First births

All births

 

 Prevalent SLE

General

Prevalent SLE

General

at delivery

Population 

at delivery

Population

N

604

18,226

1,289

45,185

Male baby, N (%)

293 (48.5)

9,303 (51.0)

631 (49.0)

23,204 (51.4)

M:F ratio

0.94

1.04

0.96

1.06

Mother born in Sweden, N (%)

542 (89.7)

16,314 (89.5)

1,145 (88.8)

39,927 (88.4)

Mother’s age, mean (SD)

28.7 (4.6)†

26.5 (5.1)

30.4 (4.8)†

28.8 (5.3)

Stilllbirth*, N (%)

7 (1.2)†

75 (0.41)

12 (0.93)†

173 (0.4)

Male baby, of live births, N (%)

290 (48.6)

9,265 (51.0)

627 (49.1)

23,113 (51.4)

RR¥ (95%CI)

0.95 (0.88, 1.04)

1.0 (ref)

0.96 (0.90, 1.01)

1.0 (ref)

 

 

 

 

Births 1997-2011φ

SLE and APS+

SLE and APS-

 

SLE and APS+

SLE and APS-

 

RR(95%CI)

0.80 (0.50, 1.25) 

0.96 (0.86, 1.08)

1.0 (ref)

0.69 (0.51, 0.94) 

0.97 (0.90, 1.05) 

1.0 (ref)

* fetal death before delivery or during delivery

† significant at alpha=0.05, chi-square test for proportions, 2-sided t-test for means

¥ RR for having a male offspring associated with a maternal SLE diagnosis

φ Presenting RR and 95% CI, restricted to 1997 onwards to account for ICD10 coding of APS.


Disclosure:

E. V. Arkema,
None;

J. Askling,
None;

J. Salmon,
None;

J. F. Simard,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sex-ratio-of-offspring-born-to-women-with-lupus-and-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology